News

25.09.2020

United We withstand the Coronavirus Crisis

For years, Synbias Pharma has been at the vanguard of anti-cancer drug production, providing much needed research and medicine in the global war against the scourge of cancer.

In May 2020, as the world was battling the coronavirus epidemic, Synbias took another major step forward when it’s subsidiary, Gemini PharmChem, began commercial production of anthracycline anti-cancer active pharmaceutical ingredients (APIs) at its Mannheim, Germany production facility.